Abstract. Background: Renal cell carcinoma (RCC) is the most common neoplasm of adult kidney accounting for about 3% of adult malignancies. P-Element induced wimpy testis (PIWI)-interacting RNAs (piRNAs) are a new class of naturally occurring, short non-coding RNAs involved in silencing of transposable elements and in sequence-specific chromatin modifications. There were preliminary data published indicating that piR-823 expression is deregulated in circulating tumor cells and tumor tissue in gastric and kidney cancer, respectively. Patients and Methods: In our study, we analyzed piR-823 levels in 588 biological specimens: tumor tissue (N = 153), adjacent renal parenchyma (N = 121), blood serum (N = 178) and urine (N = 20) of patients undergoing nephrectomy for RCC; and in blood serum (N = 101) and urine (N = 15) of matched healthy controls. Expression levels of piR-823 were determined in all biological specimens by quantitative real-time polymerase chain reaction, compared in patients and controls, and correlated with clinicopathological features of RCC. Results: We identified a significant down-regulation of piR-823 in tumor tissue [p<0.0001, area under the curve (AUC)=0.7945]. On the contrary in blood serum and urine, the expression of piR-823 was significantly higher in patients with RCC compared to healthy individuals (p=0.0005, AUC=0.6264 and p=0.0157, AUC=0.7433, respectively). We further observed higher levels of piR-823 in tumor tissue to be associated with shorter disease-free survival of patients (p=0.0186) and a trend for higher piR-823 levels in serum to be associated with advanced clinical stages of RCC (p=0.0691). There were no other significant associations of piR-823 levels in any type of biological specimen with clinicopathological features of RCC. Conclusion: piR-823 is down-regulated in tumor tissue, but positively correlated with worse outcome, indicating its complex role in RCC pathogenesis. In blood serum, piR-823 is up-regulated, but with unsatisfactory analytical performance. Preliminary data indicate the promising diagnostic utility of urinary piR-823 in patients with RCC.

Renal cell carcinoma (RCC) is the most common neoplasm of the kidney in adults, accounting for 3% of adult malignancies and having the highest mortality rate at over 40% (1). P-Element induced wimpy testis (PIWI)-interacting RNAs (piRNAs) are a newly discovered class of short non-coding RNAs such as microRNAs and siRNAs with 20-23 nucleotides in length (2). Initially, they were reported in mice testes, where they have a major role in the germ cell in maintaining genomic stability through binding to PIWI proteins and then silencing transposable elements (3). piRNA-based silencing is mediated by CpG methylation, chromatin remodeling and degradation of complementary transcripts (4). Recent studies suggest that the deregulated expression of PIWI proteins is common in tumor tissue, and PIWI expression levels are correlated to clinicopathological features and survival in patients with cancer [reviewed in (5)]. Therefore, they present promising cancer biomarkers. Recently, it was repeatedly reported that not only PIWI proteins, but also...
piRNAs can play an important role in carcinogenesis. Over- or underexpression of piRNAs that target mRNA transcripts (e.g., those containing transposon-derived sequences in their 3’ untranslated regions) could also play a driver role through degradation or inhibition of tumor-suppressor genes or oncogenes, respectively. Deregulated levels of many piRNAs were described in RCC (6, 7), gastric cancer (8, 9), hepatocellular carcinoma (10), multiple myeloma (11), lung cancer (12), bladder cancer (13), breast cancer (14) and pancreatic ductal adenocarcinoma (15). One of the first piRNAs identified as being linked to cancer is piR-823 (8).

Table I. Patient characteristics and piR-823 expression levels.

<table>
<thead>
<tr>
<th>Tissue</th>
<th>N</th>
<th>piR-823 copies*</th>
<th>Serum</th>
<th>N</th>
<th>piR-823 copies*</th>
<th>Urine</th>
<th>N</th>
<th>piR-823 copies*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenchyma, HC</td>
<td>121</td>
<td>465528±391450</td>
<td>101</td>
<td>2427±4230</td>
<td>15</td>
<td>92200±80495</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor, RCC patients</td>
<td>153</td>
<td>161841±191214</td>
<td>178</td>
<td>3828±6433</td>
<td>20</td>
<td>552264±773929</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fold-change in patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-Value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>82</td>
<td>201075±314067</td>
<td>117</td>
<td>2422±2823</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III-IV</td>
<td>48</td>
<td>151862±129437</td>
<td>60</td>
<td>3634±6378</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-Value</td>
<td>0.7852</td>
<td></td>
<td>0.0691</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fuhrman grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1-2</td>
<td>81</td>
<td>213445±316014</td>
<td>106</td>
<td>2391±2601</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G3-4</td>
<td>49</td>
<td>135291±1542</td>
<td>66</td>
<td>3621±6326</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-Value</td>
<td>0.1416</td>
<td></td>
<td>0.2096</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Association with DFS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cut-off</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-Value</td>
<td>223038</td>
<td></td>
<td>2046</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Association with OS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cut-off</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-Value</td>
<td>147727</td>
<td></td>
<td>9035</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RCC, Renal cell carcinoma; TU, tumor; RP, renal parenchyma; HC, healthy controls; AUC, area under curve; DFS, disease-free survival; OS, overall survival; NA: not available. *Data are the mean±SD.

Patients and Methods

Samples of tumor tissue (N=153), renal parenchyma (N=121), blood serum (N=178) and urine (only for the last 20 patients included) used in this study were obtained from patients diagnosed with RCC who underwent radical nephrectomy at Masaryk Memorial Cancer Institute (MMCI) in Brno or The University Hospital Brno (UHB) between 2012 and 2015. The median age of the patients at the time of diagnosis was 64 years (range=21-84 years). Blood serum (N=101) and urine samples (N=15) were also obtained from healthy individuals who underwent preventative medical examination in MMCI. Patient’s biological samples were frozen and stored at −80°C until processing. Written informed consent was obtained from all participants (patients, healthy individuals), and the study was approved by the local Ethics Boards at MMCI and UHB. Clinical and pathological characteristics are summarized in Table I.

Total RNA from tissue samples was isolated by use of mirVana miRNA Isolation Kit (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. For RNA isolation from serum, miRNeasy Serum/Plasma Kit (Qiagen, Valencia, CA, USA) was used, and for isolation from urine Urine microRNA Purification Kit (Norgen, Thorold, ON, Canada) was used. RNA concentration and purity were measured using a Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Using 10 ng of total RNA, cDNA was synthesized with TaqMan® MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific) according to the manufacturer’s recommendations. Quantitative polymerase chain reaction was performed in a total volume of 15 μl using specific probe for piR-823. The primers and probe were designed and synthesized (Thermo Fisher Scientific) to be used for determination of piR-823 sequence 5’ AGCGUUGGUGGUAUAGUGGUGAGC AUAGCGUCG-3’. The expression levels were quantified absolutely by use of a calibration curve using piR-823 plasmids synthesized by Generi Biotech (Hradec Kralove, Czech Republic).

Differences in expression levels of piR-823 between tumor tissue and renal parenchyma were evaluated by use of Wilcoxon test, and differences in serum and urine samples of patients and healthy controls were evaluated by use of Mann–Whitney test. For determining the differences according to clinical stage and grade, we used non-

6420
parametric Kruskal–Wallis test. Receiver operating curve (ROC) analysis was performed to identify cut-offs to distinguish patients with different prognoses. Kaplan–Meier survival curves and log-rank test were used for survival analysis. Calculations were performed in GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA).

**Results**

In our study, we successfully determined piR-823 expression levels in 588 biological specimens obtained from patients with RCC and healthy controls. We observed significant differences in piR-823 expression levels between tumor and non-tumor tissue samples. piR-823 expression was significantly decreased in tumor tissue compared to paired non-tumorous renal parenchyma (Figure 1, \( p < 0.0001 \)). ROC analysis showed that tissue levels of piR-823 can differentiate tumor tissue from renal parenchyma with an area under the curve (AUC) of 0.795. However, we observed no association of piR-823 levels in tumor with clinical stage or Fuhrmann grade. Interestingly, although the piR823 levels in tumor tissue were decreased, a low level was associated with a longer disease-free survival (DFS) (\( p = 0.0186 \); Figure 2). The median DFS in patients with RCC with high expression of piR-823 was 56 months, whereas in the low-expression group median was not reached. Although we observed the same trend in OS, the association of piR-823 level and OS did not reach statistical significance (\( p > 0.05 \)).

Furthermore, we recorded significantly higher levels of piR-823 in serum of patients with RCC when compared to healthy controls (\( p = 0.0005 \); Figure 3A), but ROC analysis showed this to have unsatisfactory analytical performance in distinguishing patients with RCC from controls (AUC=0.626). There was no correlation of piR-823 in serum with Fuhrmann grade, DFS or OS. We did observe a trend for higher piR-823 levels in serum to be associated with advanced clinical stages of RCC (\( p = 0.0691 \)). There was also no correlation between the piR-823 level in serum and that in paired tumor tissues samples (\( p > 0.05 \)).

Finally, we determined level of piR-823 in urinary samples of small groups of patients with RCC and healthy controls. Preliminary results showed piR-823 levels were significantly higher in urinary samples from patients with RCC in comparison to healthy controls (\( p = 0.0157 \), Figure 3B).

**Discussion**

As the first aim, we determined expression of piR-823 in paired samples of tumor tissue and adjacent renal parenchyma. In agreement with our previous pilot study (19), we observed significantly reduced expression of piR-823 in tumor tissue compared to adjacent non-tumorous renal parenchyma. Martinez et al.’s observed RCC tumors to be characterized by general down-regulation of piRNA (9). We did not find any significant association of tumor piR-823 level with clinical stage, Fuhrmann grade or OS. However, we observed significant association of tumor piR-823 and DFS, with the median DFS in patients with low expression being significantly longer.

Since piRNAs predominantly control the expression of transposable elements (20), piR-823 could be involved in maintenance of genomic stability and its frequently observed loss in RCC tumor tissues may be linked to genomic instability, which is a general hallmark of all malignant tumors. However, the link we found here to survival, where a higher levels of piR-823 is associated with worse DFS, indicates a more oncogenic than tumor-suppressive role for
piR-823 in RCC. It seems that piR823 might play a complex role in RCC pathogenesis characterized by different phenotypic effects in different stages of the disease.

In addition to transposable elements, piR-823 can potentially also target protein-coding genes. On the basis of base pair complementarity, cell-division cycle 5-like protein (CDC5L) represents a potential target of piR-823, since CDC5L contains a region which is fully complementary to piR-823. CDC5L is a cell-cycle regulator (21) whose up-regulation in tumor tissue of osteosarcoma and cervical tumors led to aberrant cell-cycle control and contributed to the malignant phenotype (22). CDC5L is a part of the E3 ubiquitin ligase complex and is required for the correct functioning of the S-phase cell-cycle checkpoint (23). It is also involved in RNA processing, where it plays an important role as a pre-mRNA splicing factor and its down-regulation reduces cell viability (22). Unfortunately, the role of CDC5L in RCC is not known.

We also analyzed piR-823 levels in blood serum and urine. We determined piR-823 expression levels in a large group of patients with RCC and gender- and age-matched healthy controls. We observed significantly higher serum levels of piR-823 in the group of patients compared to healthy individuals (p=0.0005), which is in contrast to differences we found in tissue samples. This phenomenon might be explained by active release of piR-823 by tumor cells leading to its decreased levels in tumors and increased levels in the circulation. The AUC for the ability of serum piR823 to distinguish patients with RCC from healthy controls was 0.626, which is not high enough to enable diagnostic utility. Although differences in expression does not allow usage of piR-823 as a new independent biomarker of RCC, it could potentially be useful in combination with other available biomarkers, e.g. newly described microRNA biomarkers. We did not observe any significant association of piR-823 with any clinical stage, Furhmann grade or survival. Therefore, we suggest that piR-823 is more likely linked to some of the general hallmarks of RCC pathogenesis than to the tumor features behind tumor invasion and progression of the disease.

Finally, we evaluated piR-823 levels in urine samples of pilot cohort of 20 RCC patients and 15 healthy controls. By this analysis, we identified significantly higher levels of piR-823 in urine from patients and significantly higher levels of piR-823 in urine in comparison to serum, indicating urine to be more suitable for piR-823 analysis than serum. In order to evaluate potential associations of urinary piR-823 and clinicopathological data, study on the larger cohort of patients with RCC is needed.

There are certain limitations to our study. We performed absolute quantification of piR-823 as we were not able to identify an appropriate endogenous control to be used for relative quantification. Therefore, our data might be biased due to the presence of inhibitors in the complex biological specimens. Moreover, in vitro experiments are needed to demonstrate the ability of RCC cells to release piR-823 and to evaluate whether piR-823 is exosomal, protein-bound or free. We have not performed an in vitro and in vivo study to describe functioning of piR-823 in RCC pathogenesis.

In conclusion, piR-823 is down-regulated in tumor tissue, but in tumor positively correlated with worse outcome, indicating its complex role in RCC pathogenesis. In blood serum, piR-823 is up-regulated, but with unsatisfactory...
analytical performance. Preliminary data indicate the promising diagnostic utility of urinary piR-823 in patients with RCC

Disclosure Statement
The Authors have no conflict of interest.

Acknowledgements
This work was financially supported by the Czech Ministry of Health, grant no. 15-34678A, 15-31071A, project MZ CR - RVO (MOU, 00209805), by the Ministry of Education, Youth and Sports of the Czech Republic under the project CEITEC 2020 (LQ1601) and project BBMRI CZ (LM2015089).

References

Received September 7, 2016
Revised September 28, 2016
Accepted September 29, 2016

Iliev et al: PiR-823 in Renal Cell Carcinoma